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Abstract
Background:  The use of mixed or blended protocols, that utilize both FSH and hMG, for
controlled ovarian hyperstimulation is increasing in use. To reduce the number of injections a
patient must administer, many physicians instruct their patients to mix their FSH and hMG together
to be given as a single injection. Therefore, the goal of this study was to definitively determine if
the FSH and LH bioactivities of highly purified, human-derived FSH (Bravelle(R)) and highly purified
hMG (Menopur(R)) were altered by reconstituting in 0.9% saline and mixing in the same syringe.
Methods: Bravelle(R) and Menopur(R) were reconstituted in 0.9% saline and mixed in a Becton
Dickinson plastic syringe. The FSH and LH bioactivities of the products were determined after
injecting female and male rats, respectively, with Bravelle(R), Menopur(R), or a mixture of
Bravelle(R) and Menopur(R). Ratios of FSH:LH activity tested were 150:75 IU (1 vial Bravelle(R): 1
vial Menopur(R)), 300:75 IU (3 vials Bravelle(R): 1 vial Menopur(R)) or 300:225 IU (1 vial
Bravelle(R): 3 vials of Menopur(R)).
Results:  There were no statistically significant changes in either FSH or LH bioactivity that
occurred after mixing Bravelle(R) with Menopur(R) in the same syringe. The theoretical vs. actual
FSH bioactivity for Bravelle(R) and Menopur(R) were 75 vs. 76.58 IU/mL and 75 vs. 76.0 IU/mL,
respectively. For the 3 ratios of FSH:LH activity tested, 150:75 IU (1 vial Bravelle(R): 1 vial
Menopur(R)), 300:75 IU (3 vials Bravelle(R): 1 vial Menopur(R)) or 300:225 IU (1 vial Bravelle(R):
3 vials of Menopur(R)) tested, the theoretical vs. actual FSH bioactivities were 150 vs. 156.86 IU/
mL, 300 vs. 308.69 IU/mL and 300 vs. 306.58 IU/mL, respectively. The theoretical vs. actual LH
bioactivity for Menopur(R) in the above mentioned ratios tested were 75 vs. 77.50 IU/mL. For the
3 ratios of FSH:LH activity tested, 150:75 IU (1 vial Bravelle(R): 1 vial Menopur(R)), 300:75 IU (3
vials Bravelle(R): 1 vial Menopur(R)) or 300:225 IU (1 vial Bravelle(R): 3 vials of Menopur(R)), the
theoretical vs. actual LH bioactivities were 75 vs. 78.38 IU/mL, 75 vs. 78.63 IU/mL and 225 vs.
233.48 IU/mL, respectively.
Conclusion: Mixing human-derived FSH (Bravelle(R)) with highly purified hMG (Menopur(R)) in
the same diluent, 0.9% NaCL, does not alter the FSH or LH bioactivity of either gonadotropin
preparation.
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Introduction
Greep and co-workers [1] were the first to demonstrate
that follicle stimulating hormone (FSH) and luteinizing
hormone (LH) were distinct chemical moieties and that
both were necessary for follicular growth, ovulation and
formation of the corpus luteum. Sixteen years later, pitui-
tary-derived gonadotropin extracts were used successfully
to induce ovulation in anovulatory women [2]. Since
then, gonadotropins have been widely used to success-
fully treat infertile women with oligomenorrhea and
amenorrhea that is not secondary to ovarian failure [3].
The first commercially available gonadotropin, human
menopausal gonadotropin (hMG; Pergonal®), was puri-
fied from the urine of postmenopausal women and con-
tained approximately equal amounts of FSH and LH
activity. By adsorbing LH using anti-hCG antibodies and
filtration through gel chromatography columns, an FSH
only preparation was subsequently produced from post-
menopausal urine [4]. In 1986, urinary FSH with <1% LH
activity became available for clinical use. A preparation
devoid of LH was speculated to have a theoretical advan-
tage over hMG in controlled ovarian hyperstimulation
(COH) protocols in women with polycystic ovary syn-
drome (PCOS) since these women have elevated levels of
endogenous LH [5]. However, to date there is no convinc-
ing evidence to support that in PCOS patients, FSH alone
is more effective than hMG for COH.
Today, COH protocols that utilize both hMG and FSH,
known as mixed or blended protocols, are commonly
used in an attempt to obtain higher pregnancy rates. To
reduce the number of daily injections, physicians often
recommend that patients reconstitute the different hor-
mone preparations in the accompanying diluent and then
mix them in the same syringe. This practice raises the
question of gonadotropin compatibility, especially if
products from different manufacturers and/or different
diluents are used. Although amino acid sequences of
human and recombinant derived FSH are identical, they
differ with respect to their glycosylation profile [6]. This
can affect the chemical nature of these glycoproteins and
impact their interaction with each other in a heterogene-
ous mixture.
In a recent study [7], it was demonstrated that highly puri-
fied, human-derived FSH (Bravelle®; Ferring Pharmaceuti-
cals Inc., Suffern, New York) could be reconstituted in
0.9% saline and mixed with hMG (Repronex®; Ferring
Pharmaceuticals Inc., Suffern, New York) in the same
syringe, without any alteration of the FSH and LH bioac-
tivities of either product. The objective of the present
investigation was to determine if the FSH and LH bioac-
tivities of highly purified, human-derived FSH (Bravelle®)
and a new, highly purified hMG (Menopur®; Ferring Phar-
maceuticals Inc., Suffern, New York) were altered when




Validated methods [8], specified by the United States
Pharmacopeia (USP), were used to determine the bioac-
tivities of each product individually and subsequent mix-
tures of the two. The bioassays were performed at
Qualtech Laboratories Inc., Ocean, New Jersey. Ovarian
weights (FSH bioassay) or seminal vesicle weights (LH
bioassay) were obtained after treating prepubertal female
or male rats with Bravelle® (75 IU FSH; ≤2% LH activity),
Menopur® (75 IU FSH; 75 IU LH activity), or one of three
mixtures of Bravelle® and Menopur®: 150:75 IU (1 vial
Bravelle®:1 vial Menopur®); 300:75 IU (3 vials Bravelle®: 1
vial Menopur®); and 300:225 IU (1 vial of Bravelle®:3 vials
of Menopur®). These ratios represent a low combination
of FSH: LH activity (150:75 IU) as well as combinations
with a high FSH and low LH activity (300:75 IU) and high
FSH and high LH activity (300:225 IU). The FSH and LH
bioactivities were compared to a menotropin Reference
Standard traceable to the National Institute for Biological
Standards and Control (NIBSC).
Test Animals
In-bred Wistar female rats (n = 296) 21 days of age were
used for the FSH bioassay and Sprague Dawley male rats
(n = 248) 21 days of age were used for the LH bioassay.
The rats, certified to be free from murine viruses, were pur-
chased from Hilltop Lab Animals Inc. (Scottdale, Pennsyl-
vania). Upon arrival, the animals were weighed, their
health was assessed and they were randomized into
groups of eight. The animals were housed in polypropyl-
ene solid bottom cages with stainless steel wire lids con-
taining shredded Aspen shavings. The animal room was
maintained at 18–19°C with a relative humidity of
approximately 50% and 12:12 hour, light: dark cycle. Rats
were given Purina rodent diet and tap water ad libitum.
For both the FSH and LH assays, one group of rats (N = 8)
was assigned to each of the low, middle, and high concen-
tration groups for each gonadotropin, gonadotropin mix-
ture and Reference Standard. Each assay was done in
duplicate, Therefore, for the FSH assay, 48 rats each were
assigned to six groups: Bravelle®, Menopur®, the three
ratios of Bravelle®  plus Menopur®, and the Reference
Standard. For the LH assay, 48 rats each were assigned to
five groups: Menopur®, the three ratios of Bravelle® plus
Menopur®, and the Reference Standard. In addition, there
was a control group in each assay that had eight rats
treated with diluent alone.Reproductive Biology and Endocrinology 2005, 3:61 http://www.rbej.com/content/3/1/61
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Reference Standards for the FSH and LH assays
The Reference Standard diluent used for both gonadotro-
pins was prepared by dissolving 10.75 g disodium hydro-
gen phosphate, 7.6 g sodium chloride and 1.0 g bovine
serum albumin in 1.0 liter of distilled water. The pH of the
solution was adjusted to 7.2 ± 0.2 with 1 N sodium
hydroxide.
As per the USP, for the FSH assay 70,000 units of hCG
were added to the Reference Standard diluent. A menotro-
pin Reference Standard (Ferring, lot-DPH12250397,
122.2 FSH IU/mg, traceable to NIBSC) was reconstituted
and diluted in the Reference Standard diluent to the final
concentrations of 1.9, 3.8 and 7.6 IU/0.6 mL.
For the LH assay, a menotropin Reference Standard (Fer-
ring, lot-DPH12250397, 99.3 LH IU/mg, traceable to
NIBSC) was reconstituted and diluted in the Reference
Standard diluent to the final concentrations of 7, 14, and
28 IU/0.8 mL.
The Reference Standard concentrations were established
in a geometric progression for the low, middle and high
doses respectively, based on previous dose response stud-
ies. The lowest concentration in this three-dose range pro-
duces a definite response in some of the rats as compared
to the control group and the highest concentration pro-
duces a submaximal to maximal response.
Gonadotropin Assays
Bravelle® and Menopur® single solutions
For the FSH assay, four vials of Bravelle® (lot-FMA001) or
Menopur®  (lot-FHA004ULB) were each individually
reconstituted with 1.0 mL of 0.9% saline and pooled.
Each solution was adjusted with Reference Standard dilu-
ent to the same three concentrations as the reference
standard (1.9, 3.8 and 7.6 IU/0.6 mL). For the LH assay,
fourteen vials of Menopur® were each individually recon-
stituted with 1.0 mL of 0.9% saline and pooled. The solu-
tion was adjusted with Reference Standard diluent to the
same three concentrations as the reference standard (7, 14
and 28 IU/0.8 mL).
Analyte (Mixture of Bravelle® and Menopur®)
150:75 IU; FSH: LH
For both the FSH and LH bioassay 20 vials of Bravelle®
(lot-FMA001) were each individually reconstituted with
1.0 mL of 0.9% saline and pooled. For the FSH assay, two
vials of Menopur® (lot-FHA004ULB) were each individu-
ally reconstituted with 1.0 mL of the Bravelle mixture and
pooled. For the LH assay analyte, 14 vials of Menopur®
(lot-464-891) were each individually reconstituted with
1.0 mL of the Bravelle® mixture and pooled.
300:75 IU; FSH: LH
For both the FSH and LH bioassay 56 vials of Bravelle®
(lot-FMA001) were each individually reconstituted with
0.5 mL of 0.9% saline and pooled (diluent A). Another 20
vials of Bravelle® (lot-FMA001) were each individually
reconstituted with 1.0 mL of diluent A and pooled (dilu-
ent B). For the FSH assay, two vials of Menopur® (lot-
FHA004ULB) were each individually reconstituted with
1.0 mL of diluent B and pooled. For the LH assay analyte,
14 vials of Menopur® (lot-FHA004ULB) were each recon-
stituted with 1.0 mL of diluent B and pooled.
300:225 IU; FSH: LH
For both the FSH and LH bioassay, 29 vials of Menopur®
(lot-FHA004ULB) were each individually reconstituted
with 0.5 mL of 0.9% saline and pooled (diluent A).
Another 10 vials of Menopur® (lot-FHA004ULB) were
individually reconstituted with 1.0 mL of diluent A and
pooled (diluent B). For the FSH assay, two vials of Brav-
elle® (lot-FMA001) were each reconstituted with 1.0 mL of
diluent B and pooled. For the LH assay, five vials of Brav-
elle® (lot-FMA001) were each individually reconstituted
with 1.0 mL of diluent B and pooled.
For all mixtures, reconstitution and pooling were done
with commercially available BD plastic syringes. The solu-
tions were further diluted to the same three concentra-
tions as the Reference Standard with Reference Standard
diluent: 1.9; 3.8; and 7.6 IU/0.6 mL for the FSH assay and
7; 14; and 28 IU/0.8 mL for the LH assay.
Control Solution
The Reference Standard diluent was used as the control
solution for both assays.
FSH assay
Each female rat was injected subcutaneously with 0.2 mL
of the assigned dose at approximately the same time of
day for three consecutive days. Twenty-four hours after the
last injection, rats were sacrificed in a carbon dioxide
chamber. Left and right ovaries were carefully dissected
from each rat, freed of fat or fibrous tissue, dried by gentle
blotting on absorbent paper and weighed on an analytical
balance. For each rat, the left and right ovarian weights
were recorded.
LH assay
Each male rat was injected with 0.2 mL of the assigned
dose at approximately the same time of day for four con-
secutive days. Twenty-four hours after the last injection,
rats were sacrificed in a carbon dioxide chamber. Seminal
vesicles were carefully dissected from each rat, freed of fat
or fibrous tissue, dried by gentle blotting on absorbent
paper and weighed on an analytical balance.Reproductive Biology and Endocrinology 2005, 3:61 http://www.rbej.com/content/3/1/61
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Determination of FSH and LH bioactivity: potency 
calculations
The FSH and LH assays were 3 × 3 parallel line assays per-
formed in duplicate. For each assay, the response to three
concentrations of the test hormones and the analyte were
compared to the response of the same three concentra-
tions of the Reference Standard. The result from each rep-
licate was combined for the final result. For each replicate,
ovarian weights or seminal vesicle weights were used to
calculate potency values for FSH and LH, respectively.
For potency values to be accepted, the combined L-value
(the confidence limit) from the duplicate assays had to be
less than 0.08 (L-value set by Ferring Pharmaceuticals
Inc.) which means that the true bioactivity of the prepara-
tion was within 93–107% of the obtained result. By Fer-
ring imposed standards, in order to have accurate,
consistent assesments of bioactivity, if an L-value was not
met, the bioassay was to be repeated until the combined
L-value was less than 0.08, providing a more exacting bio-
assay. This is a more stringent criterion than specified in
the USP monograph on menotropins, which only
requires an L-value of 0.18 (a value ±21% of the obtained
result) [8].
Potency calculations were the same for the FSH and LH
bioassays. The following equations were used: M' = ciTa/
Tb; where M' = log-potency of an unknown relative to its
assumed potency; c = 4/3; i = interval in logarithms
between successive log-doses (same for standard and test
concentration); Ta = difference in responses between the
standards and the test concentrations, Tb = combined
slope of the dose-response curves for the standards and
test concentrations. After calculating M', the log-potency
was determined by the equation: M = M'+log R, (M = log
potency; for the present experiment: R = 1 making log R =
0). Therefore, potency = antilog M, and % claim = antilog
M × 100 [8]. FSH and LH bioactivities obtained by these
Table 2: Theoretical and actual FSH bioactivities for Bravelle®, Menopur®, and a mixture of Bravelle® and Menopur® when 
reconstituted in 0.9% saline and mixed in the same syringe.
Hormone (FSH:LH)a Theoretical bioactivity IU/mL (%) Actual bioactivity IU/mL (% claim) L-valueb
Bravelle® (75:0) 75 (100%) 76.58 (102.1%) 0.072
Menopur® (75:75) 75 (100%) 76.0 (101.3%) 0.072
Bravelle® + Menopur®
(150:75) 150 (100%) 156.86 (104.6%) 0.072
(300:75) 300 (100%) 308.69 (102.9%) 0.072
(300:225) 300 (100%) 306.58 (102.2%) 0.072
a Ratio of FSH:LH bioactivity expressed in IUs
b L-value refers to the confidence limit obtained after combining two replicates. The USP mandated L-value = 0.18; the more stringent L-value of 
0.08 is set by Ferring Pharmaceuticals Inc. to more precisely and consistently assess bioactivity.
Table 1: Ovarian weights in rats injected with a low, middle and a high dose of the Reference Standard, Bravelle®, Menopur®, or a 
mixture of Bravelle® and Menopur® reconstituted in 0.9% saline and mixed in the same syringe.
Hormone (FSH:LH)a Total no. rats Ovarian weights (mean ± SEM)b*
Lowc dose Middled dose Highe dose
Reference Standard 48 93.55 ± 4.17 151.37 ± 4.00 193.01 ± 5.02
Bravelle® (75:0) 48 92.31 ± 3.02 149.60 ± 3.29 201.37 ± 4.56
Menopur® (75:75) 48 92.19 ± 3.45 151.51 ± 2.62 194.92 ± 4.03
Bravelle® + Menopur®
(150:75) 48 97.29 ± 2.80 148.82 ± 3.65 199.59 ± 4.30
(300:75) 48 92.38 ± 3.37 157.08 ± 3.82 192.62 ± 5.50
(300:225) 48 95.75 ± 2.94 149.50 ± 6.11 195.39 ± 6.13
* The magnitude of this increase was similar across treatment groups (treatment × dose P = 0.71)
a Ratio of FSH:LH bioactivity expressed in IUs
b Combined ovarian weights from the 2 replicates (replicate × treatment × dose)
c Low dose = 1.9 IU FSH/0.6 mL
d Middle dose = 3.8 IU FSH/0.6 mL
e High dose = 7.6 IU FSH/0.6 mLReproductive Biology and Endocrinology 2005, 3:61 http://www.rbej.com/content/3/1/61
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assays were compared with the FSH and LH bioactivities
set forth in the product label (labeled claim).
Statistical analysis
An analysis of variance (ANOVA) was performed to deter-
mine if there were differences among ovarian or seminal
vesicle weights between replicates. This analysis included:
replicate; treatment; dose; replicate × treatment; replicate
× dose; and replicate × treatment × dose, as sources of var-
iation. Since replicate × treatment × dose analyses were
not significant (P > 0.05), ovarian weights from both rep-
licates were combined as were seminal vesicle weights for
both replicates.
An ANOVA for a randomized block design was next per-
formed to determine if there were differences in ovarian
or seminal vesicle weights among treatments. This analy-
sis included: replicate (block); treatment; dose and treat-
ment × dose, as sources of variation.
Results
FSH Bioassay
The ovarian weights (mean ± SEM) were not significantly
different among treatments (Table 1). As expected, ovar-
ian weights increased in a dose-dependent manner with
increasing doses of FSH. The magnitude of increase in
ovarian weights was similar across treatment groups
(treatment × dose, P > 0.05; Table 1), indicating that FSH
bioactivity was unaffected by either reconstitution of hor-
mones with 0.9% saline or by mixing the reconstituted
hormones in the same syringe. The theoretical and actual
FSH bioactivities for Bravelle®, Menopur® and a mixture of
Bravelle® and Menopur® are shown in Table 2. The bioac-
tivities of the five groups expressed as a percent of the
labeled claims are shown in Figure 1a.
LH Bioassay
The seminal vesicle weights (mean ± SEM) were not sig-
nificantly different among treatments (Table 3). As
expected, seminal vesicle weights increased with increas-
ing doses of LH (Table 3). The magnitude of this increase
was similar across treatment groups (treatment × dose, P
> 0.05; Table 3), indicating that LH bioactivity was unaf-
Theoretical vs. actual FSH and LH activities Figure 1
Theoretical vs. actual FSH and LH activities. A) FSH 
bioactivities of Bravelle, Menopur and the three ratios of Bra-
velle and Menopur expressed as a percent of labeled claim. 
B) LH bioactivities of Menopur and the three ratios of Brav-
elle and Menopur expressed as a percent of labeled claim.
A
B
Table 3: Seminal vesicle weights in rats injected with a low, middle and a high dose of the Reference Standard, Menopur®, or a mixture 
of Bravelle® and Menopur® reconstituted in 0.9% saline and mixed in the same syringe.
Hormone (FSH:LH)a Total no. rats Seminal Vesicle weights (mean ± SEM)b*
Lowc dose Middled dose Highe dose
Reference Standard 48 35.82 ± 1.64 68.88 ± 2.40 96.39 ± 2.95
Menopur® (75:75) 48 36.49 ± 1.54 72.55 ± 1.61 95.69 ± 2.87
Bravelle®+ Menopur®
(150:75) 48 36.47 ± 1.23 73.94 ± 2.42 96.62 ± 1.70
(300:75) 48 37.80 ± 1.25 74.57 ± 1.57 94.49 ± 2.09
(300:225) 48 36.28 ± 1.50 74.78 ± 1.78 95.73 ± 2.01
* The magnitude of this increase was similar across treatment groups (treatment × dose P = 0.74)
a Ratio of FSH:LH bioactivity expressed in IUs
b Combined seminal vesicle weights from the 2 replicates (replicate × treatment × dose)
c Low dose = 7 IU LH/0.8 mL
d Middle dose = 14 IU LH/0.8 mL
e High dose = 28 IU LH/0.8 mLReproductive Biology and Endocrinology 2005, 3:61 http://www.rbej.com/content/3/1/61
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fected by either reconstitution of hormones with 0.9%
saline or by mixing the hormones in the same syringe. The
theoretical and actual bioactivities for Menopur® and a
mixture of Bravelle® and Menopur® are shown in Table 4.
The bioactivities of the four groups expressed as a percent
of the labeled claims are shown in Figure 1b.
While Bravelle® contains up to 2% LH, due to the small
amount, for this assay it is assumed that Bravelle® does not
contain LH activity.
For both the FSH and LH bioassays, the L-value obtained
was less than 0.08 which means that the true bioactivity is
within 93–107% of the obtained result. Since all of the
required USP specifications for the bioassays were met, it
is concluded that the resulting bioactivity for LH and FSH
in the mixed preparations was unaffected by reconstitut-
ing Bravelle® and Menopur® in 0.9% saline and mixing in
a BD plastic syringe.
Discussion
In many cases, physicians are administering FSH and
hMG as separate injections because of concerns that dif-
ferent gonadotropins may not be compatible, which
could result in unexpected results during controlled ovar-
ian hyperstimulaiton (COH) cycles. This concern for com-
patibility has merit since different gonadotropins are
either from animal or human origin and use different
diluents for reconstitution and/or require different deliv-
ery systems. It is well known that even structurally similar
proteins, expecially those of high molecular weight can be
incompatible. FSH, LH and hCG gonadotropins have
high molecular weight (27–31 kD) and require sur-
factants to prevent sticking. Nonetheless, in an effort to
minimize the number of injections that a woman must
take while undergoing COH, some physicians are com-
bining FSH and hMG in the same syringe. The charge dis-
tribution (described by the isoelectric point) and the
carbohydrate complexity (simple, intermediate and com-
plex carbohydrates) of recombinant FSH was found to be
quite different when compared with serum FSH through-
out the menstrual cycle [11]. Therefore, when hormones
with different chemical configurations are reconstituted
in different diluents and mixed, their compatibility and
possibly their bioactivity may be affected.
A previous study demonstrated that the activity of pep-
tides may be significantly changed by the diluents in
which they are dissolved [12] or the characteristic of the
vessel used for mixing. Studies have shown that peptides
and proteins adhere to certain surfaces [13]. Surface
adsorption of calcitonin on soda lime silica glass is pH
dependent [13]. Fibrinogen adheres to both dimethyl-
dichlorosilane-treated glass and low-density polyethylene
[14].
We must emphasize that the results from this study and a
previously published study [7] were obtained with FSH
and LH activity containing preparations from a single
manufacturer (Ferring Pharmaceuticals Inc.) and that the
hormone preparations were reconstituted and mixed
according to the manufacturer's directions. These data
cannot be extended to other preparations of gonadotro-
pins, particularly if recombinant hormones that require
bacteriostatic water for reconstitution or other delivery
vehicles are mixed with human-derived hormone prepa-
rations.
In summary, the results of this study confirm those of a
previous study [7] combining Bravelle® with Repronex®.
The present study was conducted because Menopur is a
more highly-purified hMG than Repronex®, thereby
resulting in significantly fewer injection site reactions
[15]. Since Menopur is now commercially available for
use in ART, it is important for doctors to have confidence
that Bravelle® and Menopur® can be reconstituted with
0.9% saline (diluent provided by the manufacturer) and
mixed together in a commercially available syringe with-
out altering the FSH or LH bioactivity. The health care
provider can be assured that the expected doses of FSH
and LH will be delivered, with no alteration in bioactivity
of either Bravelle® or Menopur®.
Table 4: Theoretical and actual LH bioactivities for Menopur®, and a mixture of Bravelle® and Menopur® when reconstituted in 0.9% 
saline and mixed in the same syringe.
Hormone (FSH:LH)a Theoretical bioactivity IU/mL (%) Actual bioactivity IU/mL (% claim) L-valueb
Menopur® (75:75) 75 (100%) 77.50 (103.3%) 0.061
Bravelle® + Menopur®
(150:75) 75 (100%) 78.38 (104.5%) 0.061
(300:75) 75 (100%) 78.63 (104.8%) 0.061
(300:225) 225 (100%) 233.48 (103.8%) 0.061
a Ratio of FSH:LH bioactivity expressed in IUs
b L-value refers to the confidence limit obtained after combining two replicates. The USP mandated L-value = 0.18; the more stringent L-value of 
0.08 is set by Ferring Pharmaceuticals Inc. to more precisely and consistently assess bioactivity.Publish with BioMed Central    and   every 
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